Clinical trial · no report yet · Phase 1/Phase 2
Agni-01
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- NCT06060613 ↗
- Recruiting
- Obsidian Therapeutics, Inc.
- 17 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 8 | |
| Podcasts | 6 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Tumor Skin; Metastatic Melanoma; Melanoma; Lung Cancer; Metastatic Lung Cancer; Non Small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer
- Interventions
- OBX-115
- Arms
- Participants with advanced solid tumors · Experimental
- Enrollment
- 254 (estimated)
- Primary outcomes
- Incidence and nature of dose-limiting toxicities (DLTs)
- The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1
- The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1
- Sponsor
- Obsidian Therapeutics, Inc.
- Start
- Oct 25, 2023
- Primary completion
- Jun 30, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06060613 · updated Oct 5, 2026